Cargando…

Acquired Hemophilia A: A Frequently Overlooked Autoimmune Hemorrhagic Disorder

Acquired hemophilia A (AHA) is a rare hemorrhagic disease in which autoantibodies against coagulation factor VIII- (FVIII-) neutralizing antibodies (inhibitors) impair the intrinsic coagulation system. As the inhibitors developed in AHA are autoantibodies, the disease may have an autoimmune cause an...

Descripción completa

Detalles Bibliográficos
Autores principales: Sakurai, Yoshihiko, Takeda, Tomohiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3987878/
https://www.ncbi.nlm.nih.gov/pubmed/24741588
http://dx.doi.org/10.1155/2014/320674
_version_ 1782311945541517312
author Sakurai, Yoshihiko
Takeda, Tomohiro
author_facet Sakurai, Yoshihiko
Takeda, Tomohiro
author_sort Sakurai, Yoshihiko
collection PubMed
description Acquired hemophilia A (AHA) is a rare hemorrhagic disease in which autoantibodies against coagulation factor VIII- (FVIII-) neutralizing antibodies (inhibitors) impair the intrinsic coagulation system. As the inhibitors developed in AHA are autoantibodies, the disease may have an autoimmune cause and is often associated with autoimmune disease. Although acute hemorrhage associated with AHA may be fatal and is costly to treat, AHA is often unrecognized or misdiagnosed. AHA should thus be considered in the differential diagnosis particularly in postpartum women and the elderly with bleeding tendency or prolonged activated partial thromboplastin time. Cross-mixing tests and measurement of FVIII-binding antibodies are useful to confirm AHA diagnosis. For treatment of acute hemorrhage, hemostatic therapy with bypassing agents should be provided. Unlike in congenital hemophilia A with inhibitors, in which immune tolerance induction therapy using repetitive infusions of high-dose FVIII concentrates is effective for inhibitor eradication, immune tolerance induction therapy has shown poor efficacy in treating AHA. Immunosuppressive treatment should thus be initiated to eradicate inhibitors as soon as the diagnosis of AHA is confirmed.
format Online
Article
Text
id pubmed-3987878
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-39878782014-04-16 Acquired Hemophilia A: A Frequently Overlooked Autoimmune Hemorrhagic Disorder Sakurai, Yoshihiko Takeda, Tomohiro J Immunol Res Review Article Acquired hemophilia A (AHA) is a rare hemorrhagic disease in which autoantibodies against coagulation factor VIII- (FVIII-) neutralizing antibodies (inhibitors) impair the intrinsic coagulation system. As the inhibitors developed in AHA are autoantibodies, the disease may have an autoimmune cause and is often associated with autoimmune disease. Although acute hemorrhage associated with AHA may be fatal and is costly to treat, AHA is often unrecognized or misdiagnosed. AHA should thus be considered in the differential diagnosis particularly in postpartum women and the elderly with bleeding tendency or prolonged activated partial thromboplastin time. Cross-mixing tests and measurement of FVIII-binding antibodies are useful to confirm AHA diagnosis. For treatment of acute hemorrhage, hemostatic therapy with bypassing agents should be provided. Unlike in congenital hemophilia A with inhibitors, in which immune tolerance induction therapy using repetitive infusions of high-dose FVIII concentrates is effective for inhibitor eradication, immune tolerance induction therapy has shown poor efficacy in treating AHA. Immunosuppressive treatment should thus be initiated to eradicate inhibitors as soon as the diagnosis of AHA is confirmed. Hindawi Publishing Corporation 2014 2014-03-24 /pmc/articles/PMC3987878/ /pubmed/24741588 http://dx.doi.org/10.1155/2014/320674 Text en Copyright © 2014 Y. Sakurai and T. Takeda. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Sakurai, Yoshihiko
Takeda, Tomohiro
Acquired Hemophilia A: A Frequently Overlooked Autoimmune Hemorrhagic Disorder
title Acquired Hemophilia A: A Frequently Overlooked Autoimmune Hemorrhagic Disorder
title_full Acquired Hemophilia A: A Frequently Overlooked Autoimmune Hemorrhagic Disorder
title_fullStr Acquired Hemophilia A: A Frequently Overlooked Autoimmune Hemorrhagic Disorder
title_full_unstemmed Acquired Hemophilia A: A Frequently Overlooked Autoimmune Hemorrhagic Disorder
title_short Acquired Hemophilia A: A Frequently Overlooked Autoimmune Hemorrhagic Disorder
title_sort acquired hemophilia a: a frequently overlooked autoimmune hemorrhagic disorder
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3987878/
https://www.ncbi.nlm.nih.gov/pubmed/24741588
http://dx.doi.org/10.1155/2014/320674
work_keys_str_mv AT sakuraiyoshihiko acquiredhemophiliaaafrequentlyoverlookedautoimmunehemorrhagicdisorder
AT takedatomohiro acquiredhemophiliaaafrequentlyoverlookedautoimmunehemorrhagicdisorder